Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Galenica to Acquire Relypsa for $32 per Share (RLYP)

Galenica has announced a tender offer to acquire all shares of Relypsa for $32 per share which on a fully…
Read more…

Relypsa: Company Releases Veltassa Launch Metrics for May (RLYP, $18.14, Buy)

Investment Thesis

Veltassa continues its slow but steady launch. The May results were in line with my projections and I…
Read more…

Relypsa: Comments on Possible Outcomes of ZS-9 PDUFA Date

I have previously written that the Veltassa launch sales figures are not likely to excite investors for some time. However,…
Read more…

Relypsa: Analyzing April Results of the Veltassa Launch (RLYP, Buy, $14.00)

Investment Overview

Investors are closely watching the launch progress of Veltassa following its December 2015 introduction. Medicare and managed care have set…
Read more…

Relypsa: Comments on Takeover Rumors

Reason for Report

Relypsa shares surged from about $15.00 at 1 PM on Thursday April 7 to close at $24.34. This…
Read more…

Relypsa: It Is Early Days in the Launch of Veltassa but the Momentum Seems Quite Strong (RLYP, Buy, $13.46)

Investment Perspective

Investors are closely watching the launch progress of Veltassa follwoing its December 2015 introduction. Medicare and managed care have…
Read more…

Relypsa: An In-depth Analysis of Early Results of the Veltassa Launch (RLYP, Buy, $13.26)

Investment Perspective

Relypsa is about two months into the launch of Veltassa, its first product. There was a time (several years…
Read more…